Presentation Outline ICHP Annual Meeting September 13-15

Special thanks to:
• Carol Heunisch, PharmD, BCPS
• Nancy Lechowicz, RN, MS
• Monica Sherlock, Sherlock RN RN, MSN
• Rita Walter, RN, MS
• Mary Keegan, RN, MS
Questions?
Contact Information:
Tim Humlicek, PharmD
Rush University Medical Center
timothy timothy_j_humlicek@rush.edu
j humlicek@rush edu
References
1. Drug Enforcement Administration. http://www.justice.gov/dea/ . Accessed July 31, 2011.
2. Drug Enforcement Administration. Oxycodone theft & loss incidents: January 2000 through June
2003. http://www.deadiversion.usdoj.gov/drugs_concern/oxycodone/oxylosses_oct2003_1.pdf.
Accessed July 28, 2011
3. Keenly P, Uselton JP. Maintain Compliance with Joint Commission Medication Management
Standards. http://www.psqh.com/julaug08/medication.html. Accessed July 28, 2011.
4. Inciardi JA et al. Mechanisms of Prescription Drug Diversion Among Drug‐Involved Club‐and
Street‐Based Populations..Pain Med. 2007;8(2):171‐183
5. O’Neal B, Siegel J. Diversion in the Pharmacy. Hosp Pharm. 2007;42(2):145‐148
66. McClure SR SR, O’neal O neal BC BC, Grauer D, D Couldry RJ RJ, King AR AR. Compliance with Recommendations for
Prevention and Detection of Controlled‐substance Diversion in Hospitals. Am J Health‐Syst
Pharm. 2011;68(8):689‐94.
7. Siegel J, Wierwille C, O’neal B. The Investigative Process. Hosp Pharm. 2007:42(2);466‐469
8. Siegel J, O’Neal B. Code N: Multidisciplinary Approach to Proactive Drug Diversion Prevention.
Hosp Pharm. 2007:42(2);244‐248
8/29/2012
6